Pharmaceutical maker Novartis AG said Tuesday a U.S. clinical study suggests that half a dose of its swine flu vaccine may be sufficient to protect people from the virus and could allow many more to be immunized with current supplies.

Clinical trials of around 4,000 individuals have shown that half the current dose of its U.S.-approved vaccine Fluvirin gives immunity to adults, the Swiss drug maker said in a statement.